Embolization of Hepatic Arteriovenous Shunt with Absolute Ethanol in a Patient with Hepatocellular Carcinoma

Senokuchi, Terutoshi; Baba, Yasutaka; Hayashi, Shinya; Nakajo, Masayuki

doi:10.1007/s00270-010-0026-5

Cited by 6 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipiodol-related cerebral embolism is also known to occur in cases with artery-pulmonary vein shunts [21]. Thus, efflux of the embolic agent into the shunts should be avoided [20, 22], which might be achieved via prophylactic embolization of the AP shunt before TACE [22, 23]. Balloon-assisted TACE might also be useful when treating cases with AP shunts [22, 24].…”

Section: Discussionmentioning

confidence: 99%

Angiographic Findings in Patients with Hepatocellular Carcinoma Previously Treated Using Proton Beam Therapy

Takahashi

Mori

Sekino

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

Given the growing interest in using proton beam therapy (PBT) for hepatocellular carcinoma (HCC), it is possible that transarterial chemoembolization (TACE) could be used for selected patients who have previously undergone PBT. However, these cases can be technically challenging to treat and require appropriate preparation. Thus, we aimed to identify angiographic findings in this setting. We retrospectively identified 31 patients (28 men and 3 women, mean age: 69 years, range: 43–84 years) who underwent hepatic angiography plus TACE or transarterial infusion chemotherapy (TAI) for HCC that recurred after PBT (July 2007 to June 2018). We discovered four angiographic findings, which we speculate were related to the previous PBT. 18 patients experienced recurrence in the irradiated field, and 13 patients experienced recurrence outside the irradiated field. 29 patients underwent TACE and only 2 patients underwent TAI. The mean number of previous PBT treatments was 1.3 ± 0.6 (range: 1–4). The median interval from the earliest PBT treatment to hepatic angiography was 559 days (range: 34–5,383 days), and the median interval from the latest PBT treatment to hepatic angiography was 464 days (range: 34–5,383 days). Abnormal staining of the irradiated liver parenchyma was observed in 22 patients, which obscured the angiographic tumor staining in 4 patients. Development of a tortuous tumor feeder vessel was observed in 13 patients. Development of an extrahepatic collateral pathway was observed in 7 patients. Development of an arterioportal or arteriovenous shunt was observed in 4 patients. Based on these findings, we conclude that PBT was associated with various angiographic findings during subsequent transarterial chemotherapy for recurrent HCC, and familiarity with these findings will be important in developing appropriate treatment plans.

show abstract

Section: Discussionmentioning

confidence: 99%

Angiographic Findings in Patients with Hepatocellular Carcinoma Previously Treated Using Proton Beam Therapy

Takahashi

Mori

Sekino

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…Treatment of HCC with AVS is not only conducive to transcatheter arterial chemoembolization treatment but can also can significantly reduce PP and improve liver function. [ 47 ]…”

Section: Etiological Treatment Under Different Mechanismsmentioning

confidence: 99%

“…Treatment of HCC with AVS is not only conducive to transcatheter arterial chemoembolization treatment but can also can significantly reduce PP and improve liver function. [47] The treatment for all the different etiologies of PH mentioned above are shown in Table 1.…”

Section: Formation Of Hepatic Arteriovenous Shuntsmentioning

confidence: 99%

Attach importance to the individualized treatment of adult portal hypertension based on etiology and pathogenesis: A review

2023

Medicine

View full text Add to dashboard Cite

There are many factors that can cause portal hypertension and secondary symptoms such as ascites, splenomegaly, and variceal hemorrhage, can seriously affect patients’ quality of life and even threaten their lives. In this paper, we summarize various causes of portal hypertension based on etiology and pathogenesis and give individualized treatment strategies in order to remind clinicians to pay attention to the identification of different causes and select corresponding treatment, so that patients are provided with the optimal treatment strategies and benefit from them.

show abstract

“…In patients with AV fistulas due to HCC, it is difficult to treat them by embolotherapy because fistula channels are derived from tumor vasculatures. We experienced a case of HCC whose AV fistula was successfully treated by absolute ethanol [18].…”

Section: Liver Avfs: Hccs/ Hht (Fig4)mentioning

confidence: 99%

“…(f) On macroscopic (left) and microscopic (right) specimens of the resected liver, the major part of the liver tumor shows necrosis. Reproduced from reference[18] with the permission of the publisher.…”

mentioning

confidence: 99%

Pulmonary and Other Non-Neurological Vascular Malformations: Diagnosis and Endovascular Treatment

Baba¹,

Hayashi²,

Nakajo³

2013

Arteriovenous Fistulas - Diagnosis and Management

Self Cite

View full text Add to dashboard Cite

Embolization of Hepatic Arteriovenous Shunt with Absolute Ethanol in a Patient with Hepatocellular Carcinoma

Cited by 6 publications

References 5 publications

Angiographic Findings in Patients with Hepatocellular Carcinoma Previously Treated Using Proton Beam Therapy

Angiographic Findings in Patients with Hepatocellular Carcinoma Previously Treated Using Proton Beam Therapy

Attach importance to the individualized treatment of adult portal hypertension based on etiology and pathogenesis: A review

Pulmonary and Other Non-Neurological Vascular Malformations: Diagnosis and Endovascular Treatment

Contact Info

Product

Resources

About